Alzamend Neuro, Inc.
ALZN · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $2 | $0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $1 | $3 | $1 | $1 |
| Operating Income | -$1 | -$3 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$3 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$3 | -$1 | -$1 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -1.28 | -2.22 | -0.19 |
| % Growth | 76.6% | 42.3% | -1,068.4% | – |
| EPS Diluted | -0.3 | -1.28 | -2.22 | -0.19 |
| Weighted Avg Shares Out | 3 | 2 | 1 | 6 |
| Weighted Avg Shares Out Dil | 3 | 2 | 1 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$3 | -$1 | -$1 |
| % Margin | – | – | – | – |